Theravance Biopharma, Inc. Accounts Payable
Theravance Biopharma, Inc. (TBPH) had Accounts Payable of $652.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-11
- 2026-06-30: Accounts Payable, Current $652.00K.
- 2026-03-31: Accounts Payable, Current $1.10M.
- 2025-12-31: Accounts Payable, Current $2.57M.
- 2025-09-30: Accounts Payable, Current $2.21M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $652.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.57M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $2.21M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.68M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.41M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $2.24M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.45M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.67M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.69M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.52M 10-K · filed 2025-03-07 |
| 2023-09-30 | $2.37M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.57M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.66M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $1.55M 10-K · filed 2024-03-01 |
| 2022-09-30 | $5.34M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.07M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.51M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $3.10M 10-K · filed 2023-03-01 |
| 2021-09-30 | $8.90M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $10.70M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.83M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $6.78M 10-K · filed 2022-02-28 |
| 2020-09-30 | $6.44M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $10.06M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $6.64M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $4.76M 10-K · filed 2021-02-26 |
| 2019-09-30 | $8.71M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $3.50M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $5.60M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $9.03M 10-K · filed 2020-02-27 |
| 2018-09-30 | $3.75M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $3.64M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $5.08M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $5.92M 10-K · filed 2019-02-28 |
| 2017-09-30 | $5.62M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $6.41M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $3.63M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $1.73M 10-K · filed 2018-02-28 |
| 2016-09-30 | $5.35M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $7.41M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $9.09M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $18.80M 10-K · filed 2017-03-01 |
| 2015-09-30 | $5.96M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $6.33M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $4.02M 10-Q · filed 2015-05-13 |
| 2014-12-31 | $9.92M 10-K · filed 2016-03-11 |
| 2014-09-30 | $5.28M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $9.50M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $4.98M 10-Q · filed 2014-06-24 |
| 2013-12-31 | $6.94M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |